Medtronic plc (NYSE :MDT), a global leader of healthcare technology, announced today that the U.S. Centers for Medicare & Medicaid Services will expand Medicare coverage for all types continuous glucose monitors (CGMs) including adjunctive and nonadjunctive CGMs. CGMs that are compatible with Medtronic insulin pumps will be covered. The rule was published on December 21st, 2021. It will become effective 60 days after publication.
“We applaud CMS for taking steps to help more people manage diabetes and giving them the ability to choose the best therapies for them,” stated Jeff Farkas (Vice President of Health Economics, Reimbursement and Government Affairs for the Diabetes business at Medtronic). This is an important benefit expansion for our customers, who have seen significant clinical and quality-of-life benefits from their integrated Medtronic insulin pumps systems. They can now get coverage for all parts of their system through Medicare.
The expanded coverage will also guarantee continuity of treatment for patients on certain Medtronic insulin pump system systems that are transitioning to Medicare. This includes Medtronic hybrid closed loop systems that automatically adjust insulin delivery based upon readings from the integrated CGM. Until the ruling is in effect, Medtronic will continue offering its CGM Access Discount for all Medicare customers.
“The CMS ruling provides much-needed relief for many people with diabetes, such as myself, who want to continue using their Medtronic insulin pump while they transition into Medicare.” Terry Weland said that he is grateful for the company’s efforts in making CGM affordable while working with CMS. “I have experienced great benefits from integrated pump therapy and I am thrilled that it opens up access to many more people who are looking for ways of improving their diabetes management. CGM technology is essential to me and others like me in order to maintain good glucose control, and better health outcomes.
